Nisa Leung Overview

  • Investor Type
  • Angel

  • Status
  • Active

  • Investments
  • 1

  • Exits
  • 1


Nisa Leung General Information


Ms. Nisa Leung serves as Director at Springhill Fund Asset Management. Ms. Leung serves as a Managing Partner at Qiming Venture Partners. She is an Angel Investor. Prior to joining Qiming, she was Co-Founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals, and healthcare services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN) and U-Systems (acquired by GE Healthcare). She was a Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital. She was named Venture Capital Professional of the Year by the Asian Venture Capital Journal in 2017. She currently sits on the board of InSilico Medicine, Horizone, Joe's Future Food, Cognitact, Zai Laboratories (NASDAQ: ZLAB), Alamar Biosciences, Belief BioMedNurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology, New Horizon Bio and Berry Oncology. She served as a Board member at Gan & Lee Pharmaceutical, VR Medical, and New Horizon Health. She also oversees Qiming's investments in Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics and Jacobio. She earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a visiting lecturer at Harvard Law School, a founding vice chair of the PhIRDA Investment Committee, a member of the Committee on Hong Kong Innovation and Technology Development and Re-Industrialization, and an advisor of Our Hong Kong Foundation. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.

Business Details

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Corporate Office
  • 4205-4206, 42/F, Gloucester Tower
  • The Landmark, Central, Hong Kong
  • Hong Kong
  • China
+86 0852 0000 0000

Nisa Leung Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Recursion Pharmaceuticals 15-Aug-2014 0000 00000 00000 Drug Discovery Generating Revenue/Not Profitable 0000 00000

Nisa Leung Exits (1)

Company Name Exit Date Exit Type Exit Size
Recursion Pharmaceuticals 16-Apr-2021 000 00000

Nisa Leung Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Nisa Leung Team (2)

Name Title Deals Funds Boards Office
Chloe Kou Executive Hong Kong, China
Nisa Leung Angel Investor 00 00 00 Hong Kong, China

Nisa Leung FAQs

  • Who is Nisa Leung?

    Nisa Leung is an angel Investor who has made 1 investment.

  • What kind of investor is Nisa Leung?

    Nisa Leung is an angel investor.

  • What does Nisa Leung do?

    As an angel investor, Nisa Leung invests personal money into promising companies, typically in exchange for equity.

  • How many board seats does Nisa Leung hold?

    Nisa Leung holds a board seat in SinoCell Technologies.

  • What has Nisa Leung invested in?

    Nisa Leung has invested in Recursion Pharmaceuticals within the Drug Discovery industry.

  • What has Nisa Leung invested in recently?

    Nisa Leung's latest investment was on 15-Aug-2014 in Recursion Pharmaceuticals, a company within the Drug Discovery industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »